DOCSLIB.ORG

SAMPLE REPORT Admera Health, LLC 126 Corporate Blvd Ā South Plainfield, NJ 07080 +1-908-222-0533Ā[email protected]

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SAMPLE REPORT Admera Health, LLC 126 Corporate Blvd Ā South Plainfield, NJ 07080 +1-908-222-0533ĀClientcare@Admerahealth.Com SAMPLE REPORT Admera Health, LLC 126 Corporate Blvd ā South Plainfield, NJ 07080 +1-908-222-0533ā[email protected] PATIENT INFORMATION SAMPLE REFERRING PHYSICIAN Name: Smith, John Date Collected: December 29, 2016 Name: Jane Doe, MD DOB: April 22, 1973 Date Received: December 29, 2016 Institution: Local Hospital Age: 43 Case ID: PGXPL16-000267 Phone: 123-456-7890 Sex: Male Source: Buccal Swabs Address: 126 Corporate Blvd. South Plainfield, NJ 07080 Comprehensive Drug Information for Smith, John ICD-10: F32.9 Major depressive disorder, single episode, unspecified; F41.9 Anxiety disorder, unspecified; F31.9 Bipolar disorder, unspecified Clopidogrel CONSIDER Alprazolam DECREASE DOSE 3ODYL[ ALTERNATIVES ;DQD[ Folic Acid Buprenorphine 6XEXWH[ Risperidone 5LVSHUGDO Fentanyl 'XUDJHVLF Thioridazine 0HOODULO Hydrocodone 9LFRGLQ Venlafaxine (IIH[RU Methadone 0HWKDGRVH Sufentanil 6XIHQWD Aripiprazole NORMAL RESPONSE Alprazolam USE CAUTION $ELOLI\ EXPECTED ;DQD[ Aripiprazole Atorvastatin $ELOLI\ /LSLWRU Iloperidone Lovastatin )DQDSW 0HYDFRU Pimozide Simvastatin 2UDS =RFRU Buspirone Buprenorphine %XVSDU 6XEXWH[ Citalopram Fentanyl &HOH[D 'XUDJHVLF Only selected drugs are listed here due to limited space. Please refer to Patient Specific Genotype Results table for comprehensive illustration of drugs in each action category. PGxOnePlus Report for Smith, John /DERUDWRU\'LUHFWRU'U-DPHV'HUPRG\&/,6,'&/,$,'' Page 1 of 31 SAMPLE REPORT Admera Health, LLC 126 Corporate Blvd ā South Plainfield, NJ 07080 +1-908-222-0533ā[email protected] Patient Specific Genotype Results and Comprehensive Drug Information for Smith, John ICD-10: F32.9 Major depressive disorder, single episode, unspecified;F41.9 Anxiety disorder, unspecified;F31.9 Bipolar disorder, unspecified Action Drug Impacted Clinical Interpretation Gene Genotype Phenotype Antiplatelets: CONSIDER CYP2C19 *1/*2 Intermediate Metabolizer &ORSLGRJUHO 3ODYL[ ALTERNATIVES (if no contraindication e.g., prasugrel, ticagrelor) Antipsychotics: CONSIDER CYP2D6 *4/*10 Intermediate Metabolizer 5LVSHULGRQH 5LVSHUGDO ALTERNATIVES (e.g., quetiapine, olanzapine, clozapine) Antipsychotics: CONSIDER CYP2D6 *4/*10 Intermediate Metabolizer 7KLRULGD]LQH 0HOODULO ALTERNATIVES Serotonin and CONSIDER CYP2D6 *4/*10 Intermediate Metabolizer Norepinephrine Reuptake ALTERNATIVES Inhibitors (SNRIs): (e.g., citalopram, sertraline) 9HQODID[LQH (IIH[RU Supplements: CONSIDER MTHFR C677T/C677T/A1298 A1298C Heterozygous Folic Acid ALTERNATIVES C Mutation/C677T Homozygous Mutation (e.g., supplements containing methylfolate) due to significantly reduced folic acid conversion Tetracyclic DECREASE DOSE CYP2D6 *4/*10 Intermediate Metabolizer Antidepressants: 0DSURWLOLQH /XGLRPLO Tricyclic DECREASE DOSE CYP2D6 *4/*10 Intermediate Metabolizer Antidepressants: by 25% $PLWULSW\OLQH (ODYLO &ORPLSUDPLQH $QDIUDQLO 'HVLSUDPLQH 1RUSUDPLQ 'R[HSLQ 'HSWUDQ ,PLSUDPLQH 7RIUDQLO 1RUWULSW\OLQH 3DPHORU 3URWULSW\OLQH 9LYDFWLO 7ULPLSUDPLQH 6XUPRQWLO Benzodiazepines: DECREASE DOSE CYP3A4 *1A/*1B Intermediate Metabolizer $OSUD]RODP ;DQD[ OR USE CAUTION PGxOnePlus Report for Smith, John /DERUDWRU\'LUHFWRU'U-DPHV'HUPRG\&/,6,'&/,$,'' Page 2 of 31 SAMPLE REPORT Admera Health, LLC 126 Corporate Blvd ā South Plainfield, NJ 07080 +1-908-222-0533ā[email protected] Action Drug Impacted Clinical Interpretation Gene Genotype Phenotype Opiates: DECREASE DOSE CYP3A4 *1A/*1B Intermediate Metabolizer %XSUHQRUSKLQH 6XEXWH[ )HQWDQ\O 'XUDJHVLF +\GURFRGRQH 9LFRGLQ 0HWKDGRQH 0HWKDGRVH OR 6XIHQWDQLO 6XIHQWD USE CAUTION due to the risk of increased exposure to the drug leading to adverse events Statins: DECREASE DOSE CYP3A4 *1A/*1B Intermediate Metabolizer $WRUYDVWDWLQ /LSLWRU to lowest necessary dose /RYDVWDWLQ 0HYDFRU daily due to Increased risk 6LPYDVWDWLQ =RFRU for myopathy and rhabdomyolysis OR USE CAUTION due to increased risk of adverse reactions Antipsychotics: USE CAUTION ANKK1 WT/c.2137G>A A1 Heterozygous &OR]DSLQH &OR]DULO due to increased risk of 2ODQ]DSLQH =DODVWD side effects including hyperprolactinemia and weight gain Antipsychotics: USE CAUTION HTR2C WT/WT rs1414334 C Allele Carrier &OR]DSLQH &OR]DULO due to increased risk of 2ODQ]DSLQH =DODVWD developing metabolic syndrome Selective Serotonin USE CAUTION CYP2D6 *4/*10 Intermediate Metabolizer Reuptake Inhibitors due to elevated risk for (SSRIs): drug overdose resulting in )OXR[HWLQH 3UR]DF adverse events and drug interaction Selective Serotonin USE CAUTION HTR1A WT/WT rs6295 CC genotype/rs1800044 C Reuptake Inhibitors due to reduced response Allele Carrier (SSRIs): )OXYR[DPLQH /XYR[ 3DUR[HWLQH 3D[LO 6HUWUDOLQH =RORIW Smoking Cessation USE CAUTION ANKK1 WT/c.2137G>A A1 Heterozygous Agents: due to reduced %XSURSLRQ :HOOEXWULQ effectiveness Statins: USE CAUTION KIF6 WT/WT rs20455 AA genotype 3UDYDVWDWLQ 3UDYDFKRO due to poorer response to statin treatment resulted from decreased risk for adverse cardiovascular events Anti-anxiety Agents: NORMAL RESPONSE HTR1A WT/WT rs6295 CC genotype/rs1800044 C %XVSLURQH %XVSDU EXPECTED Allele Carrier PGxOnePlus Report for Smith, John /DERUDWRU\'LUHFWRU'U-DPHV'HUPRG\&/,6,'&/,$,'' Page 3 of 31 SAMPLE REPORT Admera Health, LLC 126 Corporate Blvd ā South Plainfield, NJ 07080 +1-908-222-0533ā[email protected] Action Drug Impacted Clinical Interpretation Gene Genotype Phenotype Antimanic Agents: NORMAL RESPONSE ABCB1 WT/WT rs1045642 GG genotype /LWKLXP /LWKDQH EXPECTED Antipsychotics: NORMAL RESPONSE CYP3A4 *1A/*1B Intermediate Metabolizer $ULSLSUD]ROH $ELOLI\ EXPECTED Antipsychotics: NORMAL RESPONSE CYP2D6 *4/*10 Intermediate Metabolizer $ULSLSUD]ROH $ELOLI\ EXPECTED ,ORSHULGRQH )DQDSW 3LPR]LGH 2UDS Antipsychotics: NORMAL RESPONSE CYP2D6 *4/*10 Intermediate Metabolizer +DORSHULGRO +DOGRO EXPECTED Antipsychotics: NORMAL RESPONSE CYP2D6 *4/*10 Intermediate Metabolizer 3HUSKHQD]LQH 7ULODIRQ EXPECTED Antipsychotics: NORMAL RESPONSE ANKK1 WT/c.2137G>A A1 Heterozygous 9DOSURLFDFLG 'HSDNRWH EXPECTED Benzodiazepines: NORMAL RESPONSE CYP2C19 *1/*2 Intermediate Metabolizer &ORED]DP 2QIL EXPECTED Benzodiazepines: NORMAL RESPONSE UGT2B15 *1/*2 rs1902023 non-AA genotype /RUD]HSDP $WLYDQ EXPECTED 2[D]HSDP 6HUD[ Selective Serotonin NORMAL RESPONSE GRIK4 WT/WT rs1954787 TT genotype Reuptake Inhibitors EXPECTED (SSRIs): &LWDORSUDP &HOH[D Selective Serotonin NORMAL RESPONSE HTR2A WT/WT rs7997012 non-GG genotype Reuptake Inhibitors EXPECTED (SSRIs): &LWDORSUDP &HOH[D Selective Serotonin NORMAL RESPONSE CYP2C19 *1/*2 Intermediate Metabolizer Reuptake Inhibitors EXPECTED (SSRIs): &LWDORSUDP &HOH[D (VFLWDORSUDP /H[DSUR Selective Serotonin NORMAL RESPONSE SLC6A4 LA/LA HTTLPR Long Form Reuptake Inhibitors EXPECTED (SSRIs): &LWDORSUDP &HOH[D (VFLWDORSUDP /H[DSUR Selective Serotonin NORMAL RESPONSE CYP3A4 *1A/*1B Intermediate Metabolizer Reuptake Inhibitors EXPECTED (SSRIs): 9LOD]RGRQH 9LLEU\G PGxOnePlus Report for Smith, John /DERUDWRU\'LUHFWRU'U-DPHV'HUPRG\&/,6,'&/,$,'' Page 4 of 31 SAMPLE REPORT Admera Health, LLC 126 Corporate Blvd ā South Plainfield, NJ 07080 +1-908-222-0533ā[email protected] Action Drug Impacted Clinical Interpretation Gene Genotype Phenotype Selective Serotonin NORMAL RESPONSE CYP2D6 *4/*10 Intermediate Metabolizer Reuptake Inhibitors EXPECTED (SSRIs): 9RUWLR[HWLQH 7ULQWHOOL[ Serotonin and NORMAL RESPONSE CYP1A2 *1A/*1F Ultrarapid Metabolizer Norepinephrine Reuptake EXPECTED Inhibitors (SNRIs): 'XOR[HWLQH &\PEDOWD Serotonin and NORMAL RESPONSE CYP3A4 *1A/*1B Intermediate Metabolizer Norepinephrine Reuptake EXPECTED Inhibitors (SNRIs): Levomilnacipran )HW]LPD Serotonin and NORMAL RESPONSE ABCB1 WT/WT rs1045642 GG genotype Norepinephrine Reuptake EXPECTED Inhibitors (SNRIs): 1HID]RGRQH 1HIDGDU Serotonin and NORMAL RESPONSE CYP3A4 *1A/*1B Intermediate Metabolizer Norepinephrine Reuptake EXPECTED Inhibitors (SNRIs): 5HER[HWLQH (GURQD[ 7UD]RGRQH 'HV\UHO Statins: NORMAL RESPONSE SLCO1B1 *1/*1 Normal Activity 3LWDYDVWDWLQ /LYDOR EXPECTED 5RVXYDVWDWLQ &UHVWRU PGxOnePlus Report for Smith, John /DERUDWRU\'LUHFWRU'U-DPHV'HUPRG\&/,6,'&/,$,'' Page 5 of 31 SAMPLE REPORT Admera Health, LLC 126 Corporate Blvd ā South Plainfield, NJ 07080 +1-908-222-0533ā[email protected] Current Medication Information for Smith, John Action Drug Impacted Clinical Interpretation Gene Genotype Phenotype Antiplatelets: CONSIDER CYP2C19 *1/*2 Intermediate Metabolizer Plavix ALTERNATIVES (if no contraindication e.g., prasugrel, ticagrelor) Supplements: CONSIDER MTHFR C677T/C677T/A1298 A1298C Heterozygous Folic Acid ALTERNATIVES C Mutation/C677T Homozygous Mutation (e.g., supplements containing methylfolate) due to significantly reduced folic acid conversion Benzodiazepines: DECREASE DOSE CYP3A4 *1A/*1B Intermediate Metabolizer Alprazolam OR USE CAUTION Opiates: DECREASE DOSE CYP3A4 *1A/*1B Intermediate Metabolizer Methadone OR USE CAUTION due to the risk of increased exposure to the drug leading to adverse events Statins: DECREASE DOSE CYP3A4 *1A/*1B Intermediate Metabolizer Lipitor to lowest necessary dose daily due to Increased risk for myopathy and rhabdomyolysis OR USE CAUTION due to increased risk of adverse reactions Smoking Cessation USE CAUTION ANKK1 WT/c.2137G>A A1 Heterozygous Agents: due to reduced Bupropion effectiveness Vitamins: CLINICAL EVIDENCE MTHFR C677T/C677T/A1298 A1298C Heterozygous Niacin NOT SUFFICIENT C Mutation/C677T Homozygous Mutation Antibiotics: CLINICAL NA NA NA Clindamycin INTERPRETATION NOT AVAILABLE PGxOnePlus Report for Smith, John /DERUDWRU\'LUHFWRU'U-DPHV'HUPRG\&/,6,'&/,$,'' Page 6 of 31
Load more

Recommended publications
  • Print Your Symptom Diary
    MEDICATION GUIDE FETZIMA® (fet-ZEE-muh) (levomilnacipran) extended-release capsules, for oral use What is the most important information I should know about FETZIMA? FETZIMA may cause serious side effects, including: • Increased risk of suicidal thoughts or actions in some children, adolescents, and young adults. FETZIMA and other antidepressant medicines may increase suicidal thoughts or actions in some children and young adults, especially within the first few months of treatment or when the dose is changed. FETZIMA is not for use in children. o Depression or other serious mental illnesses are the most important causes of suicidal thoughts or actions. Some people may have a higher risk of having suicidal thoughts or actions. These include people who have (or have a family history of) depression, bipolar illness (also called manic-depressive illness) or have a history of suicidal thoughts or actions. How can I watch for and try to prevent suicidal thoughts and actions? o Pay close attention to any changes, especially sudden changes in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions. This is very important when an antidepressant medicine is started or when the dose is changed. o Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings. o Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms. Call your healthcare provider or
    [Show full text]
  • 624.Full.Pdf
    1521-009X/44/5/624–633$25.00 http://dx.doi.org/10.1124/dmd.115.068932 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 44:624–633, May 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Development of a Rat Plasma and Brain Extracellular Fluid Pharmacokinetic Model for Bupropion and Hydroxybupropion Based on Microdialysis Sampling, and Application to Predict Human Brain Concentrations Thomas I.F.H. Cremers, Gunnar Flik, Joost H.A. Folgering, Hans Rollema, and Robert E. Stratford, Jr. Brains On-Line BV, Groningen, The Netherlands (T.I.F.H.C., G.F. J.H.A.F.); Rollema Biomedical Consulting, Mystic, Connecticut (H.R.); and Division of Pharmaceutical Sciences, Mylan School of Pharmacy, Duquesne University, Pittsburgh, Pennsylvania (R.E.S.) Received December 11, 2015; accepted February 24, 2016 Downloaded from ABSTRACT Administration of bupropion [(6)-2-(tert-butylamino)-1-(3-chlorophenyl) concentration ratio at early time points was observed with propan-1-one] and its preformed active metabolite, hydroxybupropion bupropion; this was modeled as a time-dependent uptake clear- [(6)-1-(3-chlorophenyl)-2-[(1-hydroxy-2-methyl-2-propanyl)amino]- ance of the drug across the blood–brain barrier. Translation of the 1-propanone], to rats with measurement of unbound concentrations model was used to predict bupropion and hydroxybupropion dmd.aspetjournals.org by quantitative microdialysis sampling of plasma and brain extra- exposure in human brain extracellular fluid after twice-daily cellular fluid was used to develop a compartmental pharmacoki- administration of 150 mg bupropion. Predicted concentrations netics model to describe the blood–brain barrier transport of both indicate that preferential inhibition of the dopamine and norepi- substances.
    [Show full text]
  • Levomilnacipran (Fetzima®) Indication
    Levomilnacipran (Fetzima®) Indication: Indicated for the treatment of major depressive disorder (MDD), FDA approved July 2013. Mechanism of action Levomilnacipran, the more active enantiomer of racemic milnacipran, is a selective SNRI with greater potency for inhibition of norepinephrine relative to serotonin reuptake Compared with duloxetine or venlafaxine, levomilnacipran has over 10-fold higher selectivity for norepinephrine relative to serotonin reuptake inhibition The exact mechanism of the antidepressant action of levomilnacipran is unknown Dosage and administration Initial: 20 mg once daily for 2 days and then increased to 40 mg once daily. The dosage can be increased by increments of 40 mg at intervals of two or more days Maintenance: 40-120 mg once daily with or without food. Fetzima should be swallowed whole (capsule should not be opened or crushed) Levomilnacipran and its metabolites are eliminated primarily by renal excretion o Renal impairment Dosing: Clcr 30-59 mL/minute: 80 mg once daily Clcr 15-29 mL/minute: 40 mg once daily End-stage renal disease (ESRD): Not recommended Discontinuing treatment: Gradually taper dose, if intolerable withdrawal symptoms occur, consider resuming the previous dose and/or decrease dose at a more gradual rate How supplied: Capsule ER 24 Hour Fetzima Titration: 20 & 40 mg (28 ea) Fetzima: 20 mg, 40 mg, 80 mg, 120 mg Warnings and Precautions Elevated Blood Pressure and Heart Rate: measure heart rate and blood pressure prior to initiating treatment and periodically throughout treatment Narrow-angle glaucoma: may cause mydriasis. Use caution in patients with controlled narrow- angle glaucoma Urinary hesitancy or retention: advise patient to report symptoms of urinary difficulty Discontinuation Syndrome Seizure disorders: Use caution with a previous seizure disorder (not systematically evaluated) Risk of Serotonin syndrome when taken alone or co-administered with other serotonergic agents (including triptans, tricyclics, fentanyl, lithium, tramadol, tryptophan, buspirone, and St.
    [Show full text]
  • Levomilnacipran for the Treatment of Major Depressive Disorder
    Out of the Pipeline Levomilnacipran for the treatment of major depressive disorder Matthew Macaluso, DO, Hala Kazanchi, MD, and Vikram Malhotra, MD An SNRI with n July 2013, the FDA approved levomil- Table 1 once-daily dosing, nacipran for the treatment of major de- Levomilnacipran: Fast facts levomilnacipran pressive disorder (MDD) in adults.1 It is I Brand name: Fetzima decreased core available in a once-daily, extended-release formulation (Table 1).1 The drug is the fifth Class: Serotonin-norepinephrine reuptake symptoms of inhibitor serotonin-norepinephrine reuptake inhibi- MDD and was well Indication: Treatment of major depressive tor (SNRI) to be sold in the United States disorder in adults tolerated in clinical and the fourth to receive FDA approval for FDA approval date: July 26, 2013 trials treating MDD. Availability date: Fourth quarter of 2013 Levomilnacipran is believed to be the Manufacturer: Forest Pharmaceuticals more active enantiomer of milnacipran, Dosage forms: Extended–release capsules in which has been available in Europe for 20 mg, 40 mg, 80 mg, and 120 mg strengths years and was approved by the FDA in Recommended dosage: 40 mg to 120 mg 2009 for treating fibromyalgia. Efficacy of capsule once daily with or without food levomilnacipran for treating patients with Source: Reference 1 MDD was established in three 8-week ran- domized controlled trials (RCTs).1 cial and occupational functioning in addi- Clinical implications tion to improvement in the core symptoms Levomilnacipran is indicated for treating of depression.5
    [Show full text]
  • Premium Non-Specialty Quantity Limit List January 2016
    Premium Non-Specialty Quantity Limit List January 2016 Therapeutic Category Drug Name Dispensing Limit Anti-infectives Antibiotics DIFICID (fidaxomicin) 200 mg 2 tabs/day & 10 days/30 days SIVEXTRO (tedizolid) Solr 6 vials/30 days SIVEXTRO (tedizolid) Tabs 6 tabs/30 days ZYVOX (linezolid) 28 tabs/30 days ZYVOX (linezolid) Suspension 4 bottles (600 mL)/28 days Antifungals LAMISIL (terbinafine) 250 mg 84 days supply/180 days Antimalarial QUALAQUIN (quinine) QL varies* Antivirals, Herpetic FAMVIR (famciclovir) 125 mg 1 tab/day FAMVIR (famciclovir) 250 mg 2 tabs/day FAMVIR (famciclovir) 500 mg 21 tabs/30 days SITAVIG (acyclovir) 50 mg 2 tabs/30 days VALTREX (valacyclovir) 1000 mg 3 tabs/day VALTREX (valacyclovir) 500 mg 2 tabs/day Antivirals, Influenza RELENZA (zanamivir) QL is 40 inh per 365 days. TAMIFLU (oseltamivir) 30 mg 40 caps per 365 days TAMIFLU (oseltamivir) 45 mg, 75 mg 20 caps per 365 days TAMIFLU (oseltamivir) Suspension 360 mL/365 days Cardiology Anticoagulants ELIQUIS (apixiban) 2 tabs/day ELIQUIS (apixiban) 5 mg 3 tabs/day IPRIVASK (desirudin) 35 days supply/180 days PRADAXA (dabigatran) 2 caps/day SAVAYSA (edoxaban) 1 tab/day XARELTO (rivaroxaban) 10 mg 35 days supply/180 days XARELTO (rivaroxaban) 15 mg 2 tabs/day XARELTO (rivaroxaban) 20 mg 1 tab/day XARELTO (rivaroxaban) Starter Pack 2 starter packs/year Heart Failure CORLANOR (ivabradine) 2 tabs/day Central Nervous System ADHD Agents ADDERALL (amphetamine/dextroamphetamine) 3 tabs/day ADDERALL XR (amphetamine/dextroamphetamine mixed salts) 1 cap/day APTENSIO XR (methylphenidate)
    [Show full text]
  • Pristiq (Desvenlafaxine Succinate) – First-Time Generic
    Pristiq® (desvenlafaxine succinate) – First-time generic • On March 1, 2017, Teva launched AB-rated generic versions of Pfizer’s Pristiq (desvenlafaxine succinate) 25 mg, 50 mg, and 100 mg extended-release tablets for the treatment of major depressive disorder. — Teva launched the 25 mg tablet with 180-day exclusivity. — In addition, Alembic/Breckenridge, Mylan, and West-Ward have launched AB-rated generic versions of Pristiq 50 mg and 100 mg extended-release tablets. — Greenstone’s launch plans for authorized generic versions of Pristiq 25 mg, 50 mg, and 100 mg tablets are pending. — Lupin and Sandoz received FDA approval of AB-rated generic versions of Pristiq 50 mg and 100 mg tablets on June 29, 2015. Lupin’s and Sandoz’s launch plans are pending. • Other serotonin-norepinephrine reuptake inhibitors approved for the treatment of major depressive disorder include desvenlafaxine fumarate, duloxetine, Fetzima™ (levomilnacipran), Khedezla™ (desvenlafaxine) , venlafaxine, and venlafaxine extended-release. • Pristiq and the other serotonin-norepinephrine reuptake inhibitors carry a boxed warning for suicidal thoughts and behaviors. • According to IMS Health data, the U.S. sales of Pristiq were approximately $883 million for the 12 months ending on December 31, 2016. optumrx.com OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at optum.com. All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners. This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.
    [Show full text]
  • A Brief Overview of Psychiatric Pharmacotherapy
    A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures • Some medications discussed are not approved by the FDA for use in the population discussed/described. • Some medications discussed are not approved by the FDA for use in the manner discussed/described. • Co-Owner: – PrairieCare and PrairieCare Medical Group – Catch LLC Disclaimer The contents of this handout are for informational purposes only and are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical or psychiatric condition. Never disregard professional/medical advice or delay in seeking it because of something you have read in this handout. Material in this handout may be copyrighted by the author or by third parties; reasonable efforts have been made to give attribution where appropriate. Caveat Regarding the Role of Medication… Neuroscience Overview Mind Over Matter, National Institute on Drug Abuse, National Institutes of Health. Available at: http://teens.drugabuse.gov/mom/index.asp. http://medicineworld.org/images/news-blogs/brain-700997.jpg Neuroscience Overview Mind Over Matter, National Institute on Drug Abuse, National Institutes of Health. Available at: http://teens.drugabuse.gov/mom/index.asp. Neurotransmitter Receptor Source: National Institute on Drug Abuse Common Diagnoses and Associated Medications • Psychotic Disorders – Antipsychotics • Bipolar Disorders – Mood Stabilizers, Antipsychotics, & Antidepressants • Depressive Disorders – Antidepressants • Anxiety Disorders – Antidepressants & Anxiolytics • Attention Deficit Hyperactivity Disorder – Stimulants, Antidepressants, 2-Adrenergic Agents, & Strattera Classes of Medications • Anti-depressants • Stimulants and non-stimulant alternatives • Anti-psychotics (a.k.a.
    [Show full text]
  • Monoamine Reuptake Inhibitors in Parkinson's Disease
    Hindawi Publishing Corporation Parkinson’s Disease Volume 2015, Article ID 609428, 71 pages http://dx.doi.org/10.1155/2015/609428 Review Article Monoamine Reuptake Inhibitors in Parkinson’s Disease Philippe Huot,1,2,3 Susan H. Fox,1,2 and Jonathan M. Brotchie1 1 Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8 2Division of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, University of Toronto, 399BathurstStreet,Toronto,ON,CanadaM5T2S8 3Department of Pharmacology and Division of Neurology, Faculty of Medicine, UniversitedeMontr´ eal´ and Centre Hospitalier de l’UniversitedeMontr´ eal,´ Montreal,´ QC, Canada Correspondence should be addressed to Jonathan M. Brotchie; [email protected] Received 19 September 2014; Accepted 26 December 2014 Academic Editor: Maral M. Mouradian Copyright © 2015 Philippe Huot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The motor manifestations of Parkinson’s disease (PD) are secondary to a dopamine deficiency in the striatum. However, the degenerative process in PD is not limited to the dopaminergic system and also affects serotonergic and noradrenergic neurons. Because they can increase monoamine levels throughout the brain, monoamine reuptake inhibitors (MAUIs) represent potential therapeutic agents in PD. However, they are seldom used in clinical practice other than as antidepressants and wake-promoting agents. This review article summarises all of the available literature on use of 50 MAUIs in PD. The compounds are divided according to their relative potency for each of the monoamine transporters.
    [Show full text]
  • The Effect of Altering Brain CYP2B Activity on Nicotine Self-Administration Behaviour and Nicotine Levels in the Brain
    The Effect of Altering Brain CYP2B Activity on Nicotine Self-Administration Behaviour and Nicotine Levels in the Brain by Kristine Garcia A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Department of Pharmacology and Toxicology University of Toronto © Copyright by Kristine Garcia 2016 The Effect of Altering Brain CYP2B Activity on Nicotine Self- Administration and Nicotine Levels in the Brain Kristine Garcia Doctor of Philosophy Pharmacology and Toxicology University of Toronto 2016 Abstract Cytochrome P450 (CYP) enzymes play an important role in drug metabolism. While CYPs are abundantly expressed in the liver, where CYP-mediated drug metabolism typically occurs, these enzymes are also expressed in other tissues such as the brain. Local brain drug metabolism can influence the response to drugs that act within the brain. The CYP subfamily 2B (CYP2B) is expressed in the brain and is responsible for metabolizing many central nervous system (CNS)- acting drugs including nicotine, the main psychoactive ingredient in cigarettes. Genetic variation in human CYP2B6 is associated with greater conversion to nicotine dependence and risk of relapse in smokers without influencing peripheral nicotine metabolism. This suggests that local brain nicotine metabolism could influence nicotine levels that in turn mediate nicotine reinforcement and resulting behaviours. The role of brain CYP2B activity in nicotine reinforcement was investigated by injecting a pharmacological CYP2B inhibitor into the brain of rats that then underwent nicotine self-administration (NSA), which models smoking behaviour. Inhibitor-treatment increased NSA acquisition, motivation to obtain nicotine and the number of sessions required to extinguish behaviour, suggesting that inhibiting brain CYP2B activity can augment nicotine-reinforced behaviour.
    [Show full text]
  • Antidepressants, Other Review 04/14/2009
    Antidepressants, Other Review 04/14/2009 Copyright © 2004 - 2009 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 5181 Natorp Blvd., Suite 205 Mason, Ohio 45040 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be
    [Show full text]
  • Levomilnacipran (Fetzima) for Major Depressive Disorder SAMIRA ZAMAN, MD, and MAURA R
    STEPS New Drug Reviews Levomilnacipran (Fetzima) for Major Depressive Disorder SAMIRA ZAMAN, MD, and MAURA R. MCLAUGHLIN, MD, University of Virginia Health System, Charlottesville, Virginia STEPS new drug reviews Levomilnacipran (Fetzima) is a serotonin-norepinephrine reuptake inhibitor (SNRI) labeled cover Safety, Tolerability, for the treatment of major depressive disorder in adults.1 Effectiveness, Price, and Simplicity. Each indepen- dent review is provided by authors who have no Drug Dosage Dose form Cost* financial association with Levomilnacipran 20 mg per day for two days, 20-, 40-, 80-, $286 for 30 capsules (prices the drug manufacturer. (Fetzima) then increases to 40 mg and 120-mg are identical for 20-,40-, This series is coordinated per day (maximum = 120 capsules 80-, and 120-mg capsules) by Allen F. Shaughnessy, mg per day) PharmD, MMedEd, Con- tributing Editor. *—Estimated retail price of one month’s treatment based on information obtained at http://www.goodrx.com (accessed August 19, 2015). A collection of STEPS pub- lished in AFP is available at http://www.aafp.org/ afp/steps. SAFETY when used concurrently with a cytochrome Levomilnacipran causes few serious adverse P450 3A4 inhibitor because levomilnaci- effects, although long-term safety has not pran is partially metabolized by the liver, been established.2 As with all antidepres- and medications that inhibit the cytochrome sants, levomilnacipran carries a warning P450 3A4 system, such as ketoconazole, may of increased risk of suicidal thoughts and cause it to accumulate.1 Patients with moder- behavior in patients 24 years or younger, and ate and severe renal impairment should be it has not been studied in patients younger limited to a dosage of 80 mg per day and 40 than 18 years.1 Levomilnacipran increases mg per day, respectively.
    [Show full text]
  • Effects of Anti Depressants on Our Sleep
    Effects of Anti Depressants on our sleep There still seems to be a lot of misunderstanding about all different kinds of Anti Depressants and what they do to our sleep. When to take them and especially the consequences for narcoleptics. Let’s start with naming them. 1. TCA - Tricyclic antidepressants Chemical compounds primarily used as antidepressant, first discovered in 1950. Have been largely replaced in clinical use in most parts of the world by newer antidepressants such as SSRI. Amitriptyline, Butriptyline, Clomipramine, Desipramine, Dosulepin, Doxepin, Imipramine, Iprindole, Lofepramine, Nortriptyline, Protriptyline, Trimipramine. 2. SSRI - Selective Serotonin Reuptake Inhibitor A class of drugs that are typically used as antidepressant in the treatment of major depressive disorder and anxiety disorders. Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline. 3. SNRI – Serotonin/norepinephrine reuptake inhibitors A class of antidepressant drugs used in the treatment of major depressive disorder (MDD) and other mood disorders. Sometimes also for anxiety disorders, OCD, ADHD, chronic neuropathic pain, and fibromyalgia syndrome (FMS), and for the relief of menopausal symptoms. Venlafaxine (Effexor), Desvenlafaxine (Pristiq), Duloxetine (Cymbalta, Yentreve), Milnacipran (Dalcipran, Ixel, Savella), Levomilnacipran (Fetzima), Sibutramine (Meridia, Reductil) 4. SARI - Serotonin antagonist and reuptake inhibitor A class of drugs used mainly as antidepressants, but also as anxiolytics and hypnotics. Nefazodone (Serzone, Nefadar), Trazodone (Desyrel) 5. TeCA - Tetracyclic antidepressant A class of antidepressants introduced in the 1970s that are closely related to the tricyclic antidepressants (TCAs). Most used is Mirtazapine Maprotiline (Deprilept, Ludiomil, Psymion), Mianserin (Bolvidon, Norval, Tolvon) Mirtazapine (Remeron, Avanza, Zispin) This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.
    [Show full text]